| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 25.7 | 26.8 | 24.5 |
| Other income | 0.2 | 0.1 | 0.5 |
| Total income | 25.9 | 26.9 | 24.9 |
| Profit before exceptional items & tax | 6.4 | 6.1 | 5.9 |
| Profit before tax | 6.4 | 6.1 | 5.9 |
| Net profit | 4.2 | 4.5 | 4.3 |
| Operating margin | 24.7% | 22.7% | 23.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -2.30% |
|---|---|
| Net profit, quarter on quarter | -6.70% |
| Revenue, year on year | +4.90% |
| Operating profit, year on year | +14.80% |
| Operating profit, quarter on quarter | +3.30% |
NSE results filing, NSE: AVIENCE. Figures extracted from the filing.
Avience Biomedicals Ltd: key numbers
- Share price
- ₹342.05
- Market cap
- ₹187.6 Cr
- Revenue (annual)
- ₹52.51 Cr
- Net profit (annual)
- ₹8.75 Cr
- P/E (TTM)
- 21.4×Sector 57.8×
- Promoter holding
- 64.59%
- FII holding
- 3.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Avience Biomedicals Ltd
All →Avience Biomedicals Annual General Meeting
Avience Biomedicals Limited has scheduled its 7th Annual General Meeting for September 30, 2026. The company also announced book closure dates for the AGM.
Avience Biomedicals Other Announcement
The company informed shareholders about accessing the 7th AGM Notice and Annual Report via web links and requested KYC updates for those with unregistered emails.
Avience Biomedicals Annual General Meeting
Avience Biomedicals filed notice of its 7th AGM, set for September 30, 2026, with its FY 2025-26 Annual Report. No monetary transaction is disclosed.
Avience Biomedicals Earnings Call Transcript: Key Takeaways
Avience Biomedicals reported FY26 revenue of ₹52.51 Cr (up 16%) with EBITDA margins improving to 28.45%. Strategy focuses on shifting from trading to in-house manufacturing and scaling exports.
- Call
- Guides 60% growth
Avience Biomedicals Investor Presentation: Key Takeaways
Avience Biomedicals Limited reports 16% FY26 revenue growth with EBITDA margins expanding to 28.45%. Strategy focuses on capacity expansion via a new ₹30.18 Cr automated facility and increasing CDSCO product approvals.
- Call
- Guides 60% growth